1939 related articles for article (PubMed ID: 15851647)
21. Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).
Haywood LJ; Ford CE; Crow RS; Davis BR; Massie BM; Einhorn PT; Williard A;
J Am Coll Cardiol; 2009 Nov; 54(22):2023-31. PubMed ID: 19926008
[TBL] [Abstract][Full Text] [Related]
22. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
Leenen FH; Nwachuku CE; Black HR; Cushman WC; Davis BR; Simpson LM; Alderman MH; Atlas SA; Basile JN; Cuyjet AB; Dart R; Felicetta JV; Grimm RH; Haywood LJ; Jafri SZ; Proschan MA; Thadani U; Whelton PK; Wright JT;
Hypertension; 2006 Sep; 48(3):374-84. PubMed ID: 16864749
[TBL] [Abstract][Full Text] [Related]
23. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.
Poldermans D; Glazes R; Kargiannis S; Wernsing M; Kaczor J; Chiang YT; Yen J; Gamboa R; Fomina I
Clin Ther; 2007 Feb; 29(2):279-89. PubMed ID: 17472820
[TBL] [Abstract][Full Text] [Related]
24. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitors or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Siragy HM
Curr Hypertens Rep; 2003 Aug; 5(4):293-4. PubMed ID: 12844462
[No Abstract] [Full Text] [Related]
25. [Old or new antihypertensive drugs? Consequences from ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial].
Düsing R
Dtsch Med Wochenschr; 2003 Jan; 128(5):214-6. PubMed ID: 12557115
[No Abstract] [Full Text] [Related]
26. Blood pressure control and cardiovascular outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHAT.
Reisin E; Graves JW; Yamal JM; Barzilay JI; Pressel SL; Einhorn PT; Dart RA; Retta TM; Saklayen MG; Davis BR;
J Hypertens; 2014 Jul; 32(7):1503-13; discussion 1513. PubMed ID: 24842697
[TBL] [Abstract][Full Text] [Related]
27. [Clinical study of the month. Which initial antihypertensive? Results from the ALLHAT trial].
Scheen AJ; Krzesinski JM
Rev Med Liege; 2003 Jan; 58(1):47-52. PubMed ID: 12647599
[TBL] [Abstract][Full Text] [Related]
28. An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.
Miranda RD; Mion D; Rocha JC; Kohlmann O; Gomes MA; Saraiva JF; Amodeo C; Filho BL
Clin Ther; 2008 Sep; 30(9):1618-28. PubMed ID: 18840367
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the effects of an angiotensin converting enzyme inhibitor and a calcium antagonist in hypertensive, macroproteinuric diabetic patients: a randomised double-blind study.
O'Donnell MJ; Rowe BR; Lawson N; Horton A; Gyde OH; Barnett AH
J Hum Hypertens; 1993 Aug; 7(4):333-9. PubMed ID: 8410924
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
[TBL] [Abstract][Full Text] [Related]
31. Mortality and morbidity during and after Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: results by sex.
Oparil S; Davis BR; Cushman WC; Ford CE; Furberg CD; Habib GB; Haywood LJ; Margolis K; Probstfield JL; Whelton PK; Wright JT;
Hypertension; 2013 May; 61(5):977-86. PubMed ID: 23529173
[TBL] [Abstract][Full Text] [Related]
32. [Are all antihypertensive agents equal? Cardiovascular events in hypertensive patients randomized to treatment with doxazosin or chlorthalidone. The ALLHAT study].
Schillaci G; Verdecchia P
Ital Heart J Suppl; 2000 Sep; 1(9):1215-7. PubMed ID: 11140297
[No Abstract] [Full Text] [Related]
33. Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Wright JT; Harris-Haywood S; Pressel S; Barzilay J; Baimbridge C; Bareis CJ; Basile JN; Black HR; Dart R; Gupta AK; Hamilton BP; Einhorn PT; Haywood LJ; Jafri SZ; Louis GT; Whelton PK; Scott CL; Simmons DL; Stanford C; Davis BR
Arch Intern Med; 2008 Jan; 168(2):207-17. PubMed ID: 18227370
[TBL] [Abstract][Full Text] [Related]
34. Effects of amlodipine and lisinopril on left ventricular mass and diastolic function in previously untreated patients with mild to moderate diastolic hypertension.
Beltman FW; Heesen WF; Smit AJ; May JF; de Graeff PA; Havinga TK; Schuurman FH; van der Veur E; Lie KI; Meyboom-de Jong B
Blood Press; 1998 May; 7(2):109-17. PubMed ID: 9657538
[TBL] [Abstract][Full Text] [Related]
35. Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT.
Yamal JM; Oparil S; Davis BR; Alderman MH; Calhoun DA; Cushman WC; Fendley HF; Franklin SS; Habib GB; Pressel SL; Probstfield JL; Sastrasinh S;
J Am Soc Hypertens; 2014 Nov; 8(11):808-19. PubMed ID: 25455006
[TBL] [Abstract][Full Text] [Related]
36. A randomized and double-blind comparison of isradipine and spirapril as monotherapy and in combination on the decline in renal function in patients with chronic renal failure and hypertension.
Petersen LJ; Petersen JR; Talleruphuus U; Møller ML; Ladefoged SD; Mehlsen J; Jensen HA
Clin Nephrol; 2001 May; 55(5):375-83. PubMed ID: 11393383
[TBL] [Abstract][Full Text] [Related]
37. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R
Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
[TBL] [Abstract][Full Text] [Related]
38. Treatment-Resistant Hypertension and Outcomes Based on Randomized Treatment Group in ALLHAT.
Bangalore S; Davis BR; Cushman WC; Pressel SL; Muntner PM; Calhoun DA; Kostis JB; Whelton PK; Probstfield JL; Rahman M; Black HR;
Am J Med; 2017 Apr; 130(4):439-448.e9. PubMed ID: 27984005
[TBL] [Abstract][Full Text] [Related]
39. [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].
Oparil S; Bakir SE
Drugs; 2000; 59 Spec No 2():25-37. PubMed ID: 11002856
[TBL] [Abstract][Full Text] [Related]
40. The diabetes subgroup baseline characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial.
Bakris G; Hester A; Weber M; Dahlof B; Pitt B; Velasquez E; Staikos-Byrne L; Shi V; Jamerson K;
J Cardiometab Syndr; 2008; 3(4):229-33. PubMed ID: 19040592
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
